Joint CORP 8-K filings

The Joint Corp. announced the results of its 2026 annual meeting of stockholders, including the election of seven directors and advisory approval of executive compensation.

The Joint Corp. has amended its credit agreement to waive a default and extend its maturity date, while also reporting a 13% revenue increase and a 34% rise in net income for Q1 2026.

The Joint Corp. has entered an agreement to sell 45 corporate-managed clinics in Southern California for $2.3 million, accelerating its transition to a pure-play franchisor model.

The Joint Corp. has entered into an agreement to sell 45 company-owned or managed clinics in Southern California to Elite Chiro Group for $2.3 million.

The Joint Corp. reported increased revenues and net income for Q4 and full year 2025, driven by refranchising efforts and operational improvements, despite a decline in system-wide and comp sales.

The Joint Corp. filed an amended 8-K to correct the summary of a letter agreement with Bandera Partners LLC and Jefferson Gramm regarding board nomination and share ownership.

The Joint Corp. has reached an agreement with activist investor Bandera Partners to nominate Jefferson Gramm to its Board of Directors for the 2026 Annual Meeting.

The Joint Corp. announced the sale of 22 corporate clinics in the Southeast for $1.5 million and the termination of a $4.5 million agreement to sell 45 clinics in Southern California due to unmet closing conditions.

The Joint Corp. reported a 6% revenue increase in Q3 2025, authorized an additional $12 million for share repurchases, and announced the sale of 45 clinics as it pursues a pure-play franchisor model.

The Joint Corp. obtained lender consent for its strategic plan to refranchise all company-owned clinics and extended its revolving credit facility maturity to August 31, 2027.

The Joint Corp. announced the finalization of a separation agreement with former Chief Financial Officer Jake Singleton, detailing severance benefits and ongoing obligations.

The Joint Corp. reported a 5% revenue increase to $13.3 million in Q2 2025, alongside significant refranchising efforts, but revised full-year sales guidance downwards due to softer market trends.

The Joint Corp. announced it will restate its 2024 annual and Q1 2025 financial statements due to a misapplication of accounting guidance for assets held for sale, which is expected to reduce net losses and increase net income.

The Joint Corp. has finalized the sale of 31 company-owned clinics for $11.13 million and simultaneously acquired regional developer rights in the Northwest, aiming to strengthen its franchise-focused business model.

The Joint Corp. announced the sale of 36 corporate-owned clinics across Arizona, New Mexico, Kansas, and Missouri, while simultaneously acquiring regional developer rights for the Northwest region, aiming to enhance its profitability profile and strengthen its pure-play franchise model.

The Joint Corp. announced the appointment of Scott J. Bowman as its new Chief Financial Officer, effective June 10, 2025, replacing Jake Singleton, as the company aims to reignite growth and improve profitability.

The Joint Corp. announced the appointment of Sandi Karrmann, a seasoned global HR executive, to its Board of Directors and the authorization of a $5 million stock repurchase program, signaling confidence in its strategic direction and commitment to shareholder value.

The Joint Corp. held its annual meeting of stockholders on May 21, 2025, and all proposals, including the election of directors, approval of executive compensation, and ratification of the appointment of BDO USA, P.C. as the independent accounting firm, were approved.

The Joint Corp. announced a 7% increase in revenue but a net loss from continuing operations for Q1 2025, as it transitions to a pure-play franchisor model.

The Joint Corp. announces a 14% increase in Q4 2024 revenue and outlines strategic initiatives to strengthen its core business and expand its franchise model.

The Joint Corp. announces its 2024 operating metrics, highlighting a 9% increase in system-wide sales and progress in refranchising its corporate clinic portfolio.

The Joint Corp. has entered into an amended agreement with Bandera Partners, securing a board nominee and extending standstill provisions.

The Joint Corp. announced a 2% revenue increase to $30.2 million for Q3 2024, alongside a net loss of $3.2 million, as it continues its refranchising strategy.

The Joint Corp. has appointed Sanjiv Razdan as its new President and CEO, effective October 14, 2024, following the resignation of Peter D. Holt.

The Joint Corp. announced a 3% revenue increase and a net loss of $3.6 million for the second quarter of 2024, as it continues its refranchising strategy.

The Joint Corp. held its 2024 annual meeting, where stockholders approved the 2024 Incentive Stock Plan and elected seven directors to the board.

The Joint Corp. announced a 5% increase in revenue and a 9% increase in system-wide sales for the first quarter of 2024, alongside significant growth in franchise license sales.

The Joint Corp. announced its fourth quarter and full year 2023 financial results, highlighting revenue growth but also a net loss due to a non-cash valuation allowance and impairment charges, while initiating a refranchising program.